Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology

Detalles Bibliográficos
Autores principales: Raje, Noopur, Terpos, Evangelos, Jandial, Danielle D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631159/
https://www.ncbi.nlm.nih.gov/pubmed/31100871
http://dx.doi.org/10.3390/dj7020054
_version_ 1783435458527625216
author Raje, Noopur
Terpos, Evangelos
Jandial, Danielle D.
author_facet Raje, Noopur
Terpos, Evangelos
Jandial, Danielle D.
author_sort Raje, Noopur
collection PubMed
description
format Online
Article
Text
id pubmed-6631159
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66311592019-08-19 Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology Raje, Noopur Terpos, Evangelos Jandial, Danielle D. Dent J (Basel) Comment MDPI 2019-05-16 /pmc/articles/PMC6631159/ /pubmed/31100871 http://dx.doi.org/10.3390/dj7020054 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Raje, Noopur
Terpos, Evangelos
Jandial, Danielle D.
Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title_full Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title_fullStr Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title_full_unstemmed Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title_short Reply to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
title_sort reply to comment—osteonecrosis of the jaw in myeloma patients receiving denosumab or zoledronic acid. comment on pivotal trial by raje et al. published in lancet oncology
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631159/
https://www.ncbi.nlm.nih.gov/pubmed/31100871
http://dx.doi.org/10.3390/dj7020054
work_keys_str_mv AT rajenoopur replytocommentosteonecrosisofthejawinmyelomapatientsreceivingdenosumaborzoledronicacidcommentonpivotaltrialbyrajeetalpublishedinlancetoncology
AT terposevangelos replytocommentosteonecrosisofthejawinmyelomapatientsreceivingdenosumaborzoledronicacidcommentonpivotaltrialbyrajeetalpublishedinlancetoncology
AT jandialdanielled replytocommentosteonecrosisofthejawinmyelomapatientsreceivingdenosumaborzoledronicacidcommentonpivotaltrialbyrajeetalpublishedinlancetoncology

Ejemplares similares